Every story in this section, newest first — page 255 of 373.
OPAL Fuels (NASDAQ:OPAL) announced its fourth-quarter and full-year 2025 financial results on Monday, highlighting a year of robust operational growth and strategic capital management.
WW International (NASDAQ:WW) reported its fourth-quarter and full-year 2025 results on March 16, 2026, signaling a successful stabilization of its business model following a major financial restructuring mid-year.
Eli Lilly and Company (NYSE:LLY) on Monday announced positive topline results from the Phase 3 ADorable-1 trial evaluating EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis.
Forgent Power Solutions (NYSE:FPS) reported explosive growth for its fiscal second quarter ended December 31, 2025, as the recently public company capitalizes on the massive infrastructure buildout required for artificial intelligence and grid modernization.
Dollar Tree (NASDAQ:DLTR) reported robust financial results for its fourth quarter and full fiscal year ended January 31, 2026, underscored by the continued expansion of its "Dollar Tree 3.0" multi-price strategy.
Alto Neuroscience (NYSE:ANRO) reported its full-year 2025 financial results, highlighting a strengthened balance sheet and a disciplined approach to research and development.
Townsquare Media (NYSE:TSQ) announced its fourth-quarter and full-year 2025 financial results on March 16, 2026, marking a significant structural pivot for the Purchase, New York-based company.
KE Holdings (NYSE:BEKE), the leading integrated online and offline platform for housing transactions and services in China, reported its unaudited financial results for the fourth quarter and full year 2025.
WaterBridge Infrastructure (NYSE:WBI) reported its full-year 2025 financial results on Monday, highlighting a transformative year defined by its September initial public offering and the strategic combination of its legacy operating entities.
VNET Group (NASDAQ:VNET) reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on March 16, 2026.
Niu Technologies (NASDAQ:NIU) reported its unaudited financial results for the fourth quarter and full year 2025 on March 16, 2026, revealing a year of starkly different halves.
Accenture (NYSE:ACN) has officially closed its acquisition of Faculty, a premier UK-based artificial intelligence company recognized for its expertise in AI safety and large-scale implementation.
Micron Technology (NASDAQ:MU) announced on March 15, 2026, the formal completion of its acquisition of the P5 Tongluo site from Powerchip Semiconductor Manufacturing (PSMC).
Zepp Health (NYSE:ZEPP) reported a 43% year-over-year increase in fourth-quarter revenue, reaching $85.2 million and meeting the high end of its previous guidance.
United States regulators have released new guidance aimed at strengthening oversight of the fast-growing prediction markets sector as trading in event-based derivatives continues to expand.
Immutep (NASDAQ:IMMP) announced on March 13, 2026, that it will shut down its Phase III TACTI-004 clinical trial evaluating eftilagimod alpha ("efti") in combination with anti-PD-1 therapy for first-line non-small cell lung cancer (NSCLC).
Trinseo (NYSE:SE) reported a net loss of $546 million for the full year 2025, a result heavily impacted by $140 million in pre-tax restructuring charges and the costs associated with a comprehensive debt refinancing completed in early 2025.
Honda Motor Company (NYSE:HMC) announced a drastic retrenchment of its electrification strategy on Friday, canceling the development and production of three core electric vehicles slated for the North American market.
Recon Technology (NASDAQ:RCON) reported a significant improvement in its financial performance for the first six months of fiscal year 2026, ending December 31, 2025.
Dynagas LNG Partners (NYSE:DLNG) reported a net income of $61.6 million for the full year 2025, reflecting the continued strength of the global liquefied natural gas (LNG) shipping market.
Barinthus Biotherapeutics (NASDAQ:BRNS) has entered into a proposed all-stock business combination with Clywedog, a strategic move aimed at consolidating resources and advancing a diversified immunotherapy pipeline.
Maiden Holdings (NASDAQ:MHLD), the Hamilton, Bermuda-based reinsurance holding company, reported a net loss of $17.8 million for the fourth quarter of 2025.
Purple Biotech (NASDAQ:PPBT) posted a net loss of $26.4 million for the full year 2025, a result heavily impacted by a $20.5 million non-cash impairment of its CM24 and NT219 programs.
Xenetic Biosciences (NASDAQ:XBIO) reported a 19% increase in royalty revenue for the full year 2025, providing a financial cushion as the company moves closer to human clinical trials for its lead immuno-oncology program.
